Li Xiaoying

[Expert Profile] Li Xiaoying, Chief Physician, Professor, Doctoral Supervisor, is an authoritative expert in endocrinology and metabolism in China, working in the Department of Endocrinology, Zhongshan Hospital, Fudan University. He has long been dedicated to clinical diagnosis, treatment, and scientific research of type 1 autoimmune diabetes, hypogonadotropic hypogonadism, and other difficult endocrine diseases, and is an important leading figure in endocrinology in China.

[Education & Career] Professor Li Xiaoying graduated from Shanghai Medical University (now Shanghai Medical College of Fudan University), completed systematic clinical training at Zhongshan Hospital, and further studied at famous international endocrinology centers. He has long served as Director of the Department of Endocrinology at Zhongshan Hospital, Fudan University, holding important academic positions including Vice Chair of the Endocrinology Branch of the Chinese Medical Association. He has presided over key grants from the National Natural Science Foundation of China and the National Key R&D Program, and has accumulated profound academic achievements in the fields of endocrinology and metabolism.

[Areas of Expertise] Professor Li specializes in standardized treatment of type 1 diabetes, type 2 diabetes and its complications, difficult reproductive endocrine diseases such as hypogonadotropic hypogonadism and gonadal developmental abnormalities, as well as diagnosis and treatment of diseases of endocrine glands such as the pituitary, thyroid, and adrenal glands. He has extensive experience in precise diabetes subtyping, application of new technologies such as insulin pumps and continuous glucose monitoring, and interpretation of hormone tests for difficult endocrine diseases. He excels at managing complex cases of "difficult-to-control blood sugar and abnormal gonadal function," helping numerous patients receive precise diagnosis and treatment.

[Academic Achievements & Industry Contributions] Professor Li has led a series of clinical studies on diabetes and endocrine diseases, systematically evaluating prevention and treatment strategies for diabetes and its complications in Chinese populations, with findings published in authoritative domestic and international journals. He has participated in the development of Chinese diabetes and endocrine disease diagnosis and treatment guidelines and expert consensus statements, actively promoted early diabetes screening, standardized management, and new technology application, and led multi-center clinical research and translational medicine studies, making important contributions to improving the diagnosis and treatment level of endocrinology and metabolism in China.

[Clinical Practice & Outstanding Contributions] Professor Li has long held expert endocrinology clinics, cumulatively treating tens of thousands of patients with diabetes and various endocrine diseases, with annual outpatient volume ranking among the highest nationwide. Leading his team, he has optimized treatment plans for countless diabetes patients with "difficult-to-control blood sugar," and has identified disease causes for numerous difficult patients with abnormal gonadal function. He has repeatedly organized diabetes science popularization and free clinics, and is deeply trusted by patients and respected by peers alike. He is an outstanding expert in the field of endocrinology in China.

[Honors & Reputation] Professor Li Xiaoying serves as Director of the Department of Endocrinology at Zhongshan Hospital, Fudan University and Vice Chair of the Endocrinology Branch of the Chinese Medical Association, among other academic positions. He has presided over national-level projects including key grants from the National Natural Science Foundation of China and the National Key R&D Program, and is an authoritative expert in the field of endocrinology and metabolism in China. He has profound expertise in the diagnosis and treatment of type 1 diabetes and difficult gonadal endocrine diseases. He has led research on precise diabetes subtyping and complication prevention and treatment, promoted standardized application of new technologies such as insulin pumps and continuous glucose monitoring, participated in the development of multiple diabetes and endocrine disease diagnosis and treatment guidelines, and has research findings published in authoritative domestic and international journals. For decades on the clinical front lines, he has helped numerous diabetes patients optimize their treatment, and is deeply trusted by patients and respected by peers alike.